Recombinant human growth hormone has been used for more than 30 years and its indications have increased worldwide. There is concern that this treatment might increase mortality, but published data are scarce. We present data from the entire dataset of all eight countries of the Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) consortium, with the aim of studying long-term overall and cause-specific mortality in young adult patients treated with recombinant human growth hormone during childhood and relating this to the underlying diagnosis.
Sävendahl, L., Cooke, R., Tidblad, A., Beckers, D., Butler, G., Cianfarani, S., et al. (2020). Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. THE LANCET DIABETES & ENDOCRINOLOGY, 8(8), 683-692 [10.1016/S2213-8587(20)30163-7].
Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study
Cianfarani, Stefano;Deodati, Annalisa;
2020-08-01
Abstract
Recombinant human growth hormone has been used for more than 30 years and its indications have increased worldwide. There is concern that this treatment might increase mortality, but published data are scarce. We present data from the entire dataset of all eight countries of the Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) consortium, with the aim of studying long-term overall and cause-specific mortality in young adult patients treated with recombinant human growth hormone during childhood and relating this to the underlying diagnosis.| File | Dimensione | Formato | |
|---|---|---|---|
|
Lancet 2020.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Non specificato
Dimensione
124.08 kB
Formato
Adobe PDF
|
124.08 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
